CNTY
Century Casinos, Inc.·Consumer Cyclical
1.39
6.107%(+0.08)
Close PriceLast Updated: — ET
52W L: $1.2352W H: $2.85
CNTY NEWS
prnewswire.com
May 13
Century Casinos Announces Appointment to Top Leadership Role in the United States
COLORADO SPRINGS, Colo., May 13, 2026 /PRNewswire/ -- Century Casinos, Inc. (the "Company" or "Century Casinos") (Nasdaq Capital Market®: CNTY) announced today that Lyle Randolph, a long-term regional Vice President and General Manager of the Company, will take over as Executive Vice President of Operations for the United States.
seekingalpha.com
May 8
Century Casinos, Inc. (CNTY) Q1 2026 Earnings Call Transcript
Century Casinos, Inc. (CNTY) Q1 2026 Earnings Call Transcript
zacks.com
May 8
Century Casinos (CNTY) Reports Q1 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.67 per share a year ago.
prnewswire.com
May 8
Century Casinos, Inc. Announces First Quarter 2026 Results
All-Time Record First Quarter Net Operating Revenue COLORADO SPRINGS, Colo., May 8, 2026 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Nasdaq Capital Market®: CNTY) today announced its financial results for the three months ended March 31, 2026.
prnewswire.com
May 1
Century Casinos Announces Dates of First Quarter 2026 Earnings Release and Conference Call
COLORADO SPRINGS, Colo., May 1, 2026 /PRNewswire/ -- Century Casinos, Inc. (Nasdaq Capital Market®: CNTY) announced today that the Company will release its earnings for the first quarter 2026 on Friday, May 8, 2026.
globenewswire.com
Apr 30
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026
